The Health Technology Assessment Environment in Mainland China, Japan, South Korea, and Taiwan-Implications for the Evaluation of Diabetes Mellitus Therapies

Value in Health Regional Issues

Volumn 3, Issue 1, 2014, Pages 108-116

  Kennedy Martin, Tessa ^a   Mitchell, Beth D ^b   Boye, Kristina S ^b   Chen, Wen ^c   Curtis, Bradley H ^b   Flynn, Jennifer A ^b   Ikeda, Shunya ^d   Liu, Li ^e   Tarn, Yen Huei ^f   Yang, Bong Min ^g   Papadimitropoulos, Emmanuel ^b  

^a Kennedy Martin Health Outcomes Ltd   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c FUDAN UNIVERSITY   (China)

^d INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^e Lilly Suzhou Pharmaceutical Co Ltd   (China)

^f NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^g Seoul National University   (South Korea)

Author keywords

Asia; Diabetes mellitus; Health technology assessment; Pricing; Reimbursement

Indexed keywords

ARTICLE; CHINA; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETES MELLITUS; DRUG COST; GEOGRAPHIC DISTRIBUTION; GROSS NATIONAL PRODUCT; HEALTH CARE QUALITY; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; JAPAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; SOUTH KOREA; TAIWAN;

EID: 84901199559     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2014.03.001     Document Type: Article

References (49)

1. Ramachandran A., Snehalatha C., Shetty A.S., Nanditha A. Trends in prevalence of diabetes in Asian countries. World J Diabetes 2012, 3:110-117.
2. International Diabetes Federation. IDF Diabetes Atlas (5th ed.) Western Pacific (WP): International Diabetes Federation, 2013. Available from:. [Accessed May 31, 2013]. http://www.idf.org/diabetesatlas/5e/western-pacific.
3. Chan J.C., Malik V., Jia W., et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009, 301:2129-2140.
4. Zhang P., Zhang X., Brown J., et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:293-301.
5. Yoon K.H., Lee J.H., Kim J.W., et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006, 368:1681-1688.
6. Doherty J., Kamae I., Lee K.K., et al. What is next for pharmacoeconomics and outcomes research in Asia?. Value Health 2004, 7:118-132.
7. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The Diabetes Control and Complications Trial Research Group.
8. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117.
9. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713. UK Prospective Diabetes Study Group.
10. Ji L.N., Lu J.M., Guo X.H., et al. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health 2013, 13:602.
11. Choi Y.J., Kim H.C., Kim H.M., et al. Prevalence and management of diabetes in Korean adults: Korea National Health and Nutrition Examination Surveys 1998-2005. Diabetes Care 2009, 32:2016-2020.
12. Yu N.C., Su H.Y., Tsai S.T., et al. ABC control of diabetes: survey data from National Diabetes Health Promotion Centers in Taiwan. Diabetes Res Clin Pract 2009, 84:94-200.
13. Kobayashi M., Yamazaki K., Hirao K., et al. The status of diabetes control and antidiabetic drug therapy in Japan--a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1). Diabetes Res Clin Pract 2006, 73198-73204.
14. Chang K. Comorbidities, quality of life and patients' willingness to pay for a cure for type 2 diabetes in Taiwan. Public Health 2010, 124:284-294.
15. van Dieren S., Beulens J.W., van der Schouw Y.T., et al. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil 2010, 17(Suppl. 1):S3-S8.
16. Suzuki Y. Analysis of medical cost of complications in diabetes mellitus. Nihon Koshu Eisei Zasshi 2005, 52:652-663.
17. Kim T.H., Chun K.H., Kim H.J., et al. Direct medical costs for patients with type 2 diabetes and related complications: a prospective cohort study based on the Korean National Diabetes Program. J Korean Med Sci 2012, 27:876-882.
18. Luce B.R., Drummond M., Jonsson B., et al. EBM, HTA, and CER: clearing the confusion. Milbank Q 2010, 88:256-276.
19. Yim E.Y., Lim S.H., Oh M.J., et al. Assessment of pharmacoeconomic evaluations submitted for reimbursement in Korea. Value Health 2012, 15(Suppl):S104-S110.
20. Bae E.Y., Lee E.K. Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea. Value Health 2009, 12(Suppl. 3):S36-S41.
21. Kamae I. Value-based approaches to healthcare systems and pharmacoeconomics requirements in Asia: South Korea, Taiwan, Thailand and Japan. Pharmacoeconomics 2010, 28:831-838.
22. Drummond M.F., Schwartz J.S., Jonsson B., et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care 2008, 24:244-258.
23. Sussex J., Towse A., Devlin N. Operationalizing value-based pricing of medicines: a taxonomy of approaches. Pharmacoeconomics 2013, 31:1-10.
24. Le C., Lin L., Jun D., et al. The economic burden of type 2 diabetes mellitus in rural southwest China. Int J Cardiol 2013, 165:273-277.
25. Lee W.J., Song K.H., Noh J.H., et al. Health-related quality of life using the EuroQol 5D questionnaire in Korean patients with type 2 diabetes. J Korean Med Sci 2012, 27:255-260.
26. Sakamaki H., Ikeda S., Ikegami N., et al. Measurement of HRQL using EQ-5D in patients with type 2 diabetes mellitus in Japan. Value Health 2006, 9:47-53.
27. Cao Y., Tang X., Yang L., et al. Influence of chronic diseases on health related quality of life in middle-aged and elderly people from rural communities: application of EQ-5D scale on a Health Survey in Fangshan, Beijing. Zhonghua Liu Xing Bing Xue Za Zhi 2012, 33:17-22.
28. Choi Y.J., Lee M.S., An S.Y., et al. The relationship between diabetes mellitus and health-related quality of life in Korean adults: the fourth Korea National Health and Nutrition Examination Survey (2007-2009). Diabetes Metab J 2011, 35:587-594.
29. Sheu W.H., Ji L.N., Nitiyanant W., et al. Hypoglycemia is associated with increased worry and lower quality of life among patients with type 2 diabetes treated with oral antihyperglycemic agents in the Asia-Pacific region. Diabetes Res Clin Pract 2012, 96:141-148.
30. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007, 30:1638-1646. Mount Hood 4 Modeling Group.
31. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004, 27:2262-2265. American Diabetes Association.
32. Pollock R.F., Valentine W.J., Pilgaard T., Nishimura H. The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective. J Med Econ 2011, 14:36-46.
33. Oishi M., Yokoyama H., Abe N., et al. Time and cost involved in the care of newly registered patients with diabetes mellitus and other lifestyle diseases at diabetes clinics in Japan (JDDM 4). Diabet Med 2007, 24:1149-1155.
34. Oishi M., Abe N., Yokoyama H., et al. Observational 6-month open-label study of Japanese type 2 diabetes patients switching from NPH insulin to insulin detemir in basal-bolus regimen: 23rd article of the Japan Diabetes Clinical Data Management Study Group (JDDM23). J Int Med Res 2012, 40:787-797.
35. Stewart A., Aubrey P., Belsey J. Addressing the health technology assessment of biosimilar pharmaceuticals. Curr Med Res Opin 2010, 26:2119-2126.
36. Canadian Agency for Drugs and Technologies in Health. Common drug review consultation - subsequent entry biologics. CDR Update - Issue 92. Available from:. [Accessed January 29, 2014]. http://www.cadth.ca/en/products/cdr/cdr-update/cdr-update-92?utm_source=cdr-update-extension&utm_medium=webmail&utm_campaign=e-alert-09-18-13.
37. Association of the British Pharmaceutical Industry. ABPI position on biosimilar medicines. 2013. Available from:. [Accessed January 29, 2014]. http://www.abpi.org.uk/our-work/library/industry/Pages/biosimilars-position-paper.aspx.
38. Charles River Associates. A comparative analysis of the role and impact of health technology assessment. 2011. Available from:. [Accessed May 31, 2013]. http://www.efpia.eu/comparative-analysis-role-and-impact-health-technology-assessment.
39. Ha D., Choi Y., Kim D.U., et al. A comparative analysis of the impact of a positive list system on new chemical entity drugs and incrementally modified drugs in South Korea. Clin Ther 2011, 33:926-932.
40. Chen Y., Banta D., Tang Z. Health technology assessment development in China. Int J Technol Assess Health Care 2009, 25(Suppl. 1):202-209.
41. National Institute for Clinical Excellence. NICE signs memorandum of understanding with Chinese Ministry of Health. Available from:. [Accessed June 14, 2013]. http://www.nice.org.uk/aboutnice/niceinternational/projects/NICESignsMemorandumOfUnderstandingWithChineseMinistryOfHealth.jsp.
42. Ministry of Human Resources and Social Security. Revision Work Plan for 2009 National Drug Reimbursement List under the Basic Medical Insurance, Occupational Injury Insurance and Maternity Insurance Program. Beijing, China: Ministry of Human Resources and Social Security, 2009.
43. The National Development and Reform Commission. Guideline for Reform of Drug and Medical Service Pricing. Beijing, China: The National Development and Reform Commission, 2009.
44. Liu G.G., Fukuda T., Lee C.E., et al. Evidence-based decision-making on medical technologies in China, Japan, and Singapore. Value Health 2009, 12(Suppl. 3):S12-S17.
45. Kamae I. Overview of recent developments in HTA systems in Asia and the position in Japan. In: Korea-U.S. Healthcare Innovation Seminar 2011,"Embracing the Era of Centenarians - The Role of Innovation in Meeting Healthcare Challenges and Promoting Economic Growth." Seoul, Korea. Co-hosted by AMCHAM Korea & PhRMA. Available from:. [Accessed June 13, 2013]. http://www.amchamkorea.org/publications/upload/2011/hcseminar/IsaoKamae.pdf.
46. Ikeda S., Ikegami N., Oliver A.J., Ikeda M. A case for the adoption of pharmacoeconomic guidelines in Japan. Pharmacoeconomics 1996, 10:546-551.
47. Organisation for Economic Co-operation and Development. OECD economic surveys. 2011. Available from:. [Accessed May 31, 2013]. http://www.oecd.org/fr/economie/etudeseconomiquesparpays/47651425.pdf.
48. Ngorsuraches S., Meng W., Kim B.Y., Kulsomboon V. Drug reimbursement decision-making in Thailand, China, and South Korea. Value Health 2012, 159(Suppl):S120-S125.
49. Japan Pharmaceutical Manufacturers Association. Pharmaceutical Administration and Regulations in Japan 2012. Available from:. [Accessed July 29, 2013]. http://www.jpma.or.jp/english/parj/pdf/2012.pdf.